

Haematologica  
HAEMATOL/2019/227215  
Version 3

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076  
is an active new therapeutic strategy in lymphoma models

Eugenio Gaudio, Chiara Tarantelli, Filippo Spriano, Francesca Guidetti,  
Giulio Sartori, Roberta Bordone, Alberto J. Arribas, Luciano Cascione,  
Mario Bigioni, Giuseppe Merlino, Alessio Fiascarelli, Alessandro  
Bressan, Afua Adjeiwaa Mensah, Gaetanina Golino, Renzo Lucchini,  
Elena Bernasconi, Davide Rossi, Emanuele Zucca, Georg Stussi,  
Anastasios Stathis, Robert S. Boyd, Rachel L. Dusek, Arnima Bisht,  
Nickolas Attanasio, Christian Rohlff, Andrea Pellacani, Monica  
Binaschi, and Francesco Bertoni

Disclosures: Institutional research funds from Menarini Ricerche S.p.A. (to F.B).  
Disclosure: Mario Bigioni, Giuseppe Merlino, Alessio Fiascarelli, Alessandro Bressan,  
Andrea Pellacani, Monica Binaschi: Menarini Ricerche S.p.A. employees. Robert S. Boyd,  
Rachel L. Dusek: Oxford BioTherapeutics, Ltd employees. Nickolas Attanasio, Christian  
Rohlff: Oxford BioTherapeutics, Inc. Alberto J. Arribas: travel grant from Astra Zeneca.  
HTG Luciano Cascione: travel grant from HTG. Afua Adjeiwaa Mensah: travel grant from  
Helsinn. Davide Rossi: grant support from Gilead, AbbVie, Janssen; honoraria from Gilead,  
AbbVie Janssen, Roche; scientific advisory board fees from Gilead, AbbVie, Janssen,  
AstraZeneca, MSD. Georg Stussi: travel grants from Novartis, Celgene, Roche;  
consultancy fee from Novartis; scientific advisory board fees from Bayer, Celgene,  
Janssen, Novartis; speaker fees from Gilead. Anastasios Stathis: institutional research  
funds from: Bayer, ImmunoGen, Merck, Pfizer, Novartis, Roche; travel grant from AbbVie.  
Emanuele Zucca: institutional research funds from Celgene, Roche and Janssen; advisory  
board fees from Celgene, Roche, Mei Pharma, Astra Zeneca and Celltrion Helthcare; travel  
grants from Abbvie and Gilead; expert statements provided to Gilead, Bristol-Myers Squibb  
and MSD. Francesco Bertoni: institutional research funds from Acerta, ADC Therapeutics,  
Bayer AG, Cellestia, CTI Life Sciences, EMD Serono, Helsinn, ImmunoGen, Menarini  
Ricerche, NEOMED Therapeutics 1, Oncology Therapeutic Development, PIQR  
Therapeutics AG; consultancy fee from Helsinn, Menarini; expert statements provided to  
HTG; travel grants from Amgen, Astra Zeneca, Janssen-Cilag AG, Jazz Pharmaceuticals,  
PIQR Therapeutics AG. The other co-authors do not report any conflict of interest.

Contributions: MoB and FB provided conception and design; EG, CT,FS designed and  
performed experiments, analyzed results, and prepared figures; FG, GS, RPB, AJA, LC,  
MaB, GM, AF, AB, AAM, GG, EB: performed experiments; RL performed genotyping for  
cell identity; RSB, RLD, AB, NA, CR performed immunohistochemistry on clinical  
specimens; GS provided personnel, contributed to data interpretation and manuscript  
revision; AP, MoB provided reagents; DR, EZ, GS, AS, MoB and FB contributed to data  
interpretation; FB provided study supervision and wrote the manuscript; all authors read  
and edited the manuscript.